Peptide evidence practice

Five illustrative claim-checking scenarios. Explain the boundary between a record and its conclusion; the sourced answer key on page 2 applies these ideas to eloralintide.

Scenario 1

A chemical database lists a peptide's molecular formula. A post concludes: “That means it works for obesity.” What evidence step is missing?

Scenario 2

Suppose a placebo-controlled trial reports a mean body-weight change of −20% in one arm. Is that the same as saying every participant lost 20%?

Scenario 3

Suppose Trial A excludes type 2 diabetes, but a different combination study includes it. Can you merge their outcomes as if they were one population?

Scenario 4

An enrolling Phase 3 listing shows an enrollment goal. Does that mean those people have finished the trial and the compound is approved?

Scenario 5

A monotherapy trial does not include retatrutide. Can its result establish that eloralintide is better or safer than retatrutide?

Explained answer key

These are evidence-reading exercises, not treatment choices or dosing recommendations.

Scenario 1

Chemical identity is not clinical efficacy. A formula record can support molecular identity, while a claim of benefit needs appropriate outcome evidence.[1, 2]

Scenario 2

No. The number is an estimated arm-level mean percentage change at a defined time under the stated analysis, not a promise for each participant or the percentage of responders.[2]

Scenario 3

No. The 2025 monotherapy trial excluded type 2 diabetes; the 2026 sponsor-reported combination study included it. Both population and intervention differ.[2, 3]

Scenario 4

No. ENLIGHTEN-1's enrollment goal and enrolling status describe ongoing research, not completed outcomes or regulatory approval.[4]

Scenario 5

No. The cited 2025 trial compares eloralintide with placebo, not retatrutide; it cannot establish head-to-head superiority or comparative safety against a treatment it did not test.[2]

PAGE SOURCES

1. KEGG molecular identity: https://www.kegg.jp/entry/D12886

2. Billings et al., Phase 2: https://pubmed.ncbi.nlm.nih.gov/41207310/

3. Lilly combination announcement: https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide

4. ENLIGHTEN-1 listing: https://trials.lilly.com/en-US/trial/664295